The PPARα exogenous agonist Wy-14643 (pirinixic acid) in an IBD mouse model significantly reduced all the inflammatory parameters (Cuzzocrea et al., 2004), including decreased production of inflammatory factors that contribute to colonic damage, such as IFN-γ, IL-1β, IL-6, and TNF-α (Azuma et al., 2010). Here, TNF is linked to inflammatory bowel disease.